Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03790839 · ClinicalTrials.gov registry record · Phase 1
Drug Interaction Study Between Dorzagliatin and Sitagliptin
A Phase 1 study, sponsored by Hua Medicine Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT03790839 is a Phase 1 study that has completed, run by Hua Medicine Limited. The registered enrollment target is 15 participants.
The verdict
NCT03790839, a Phase 1 study, has completed, sponsored by Hua Medicine Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is a Phase 1, open-label, sequential, multiple-dose, drug interaction study of glucokinase activator dorzagliatin and sitagliptin in subjects with T2DM. Pharmacokinetics and pharmacodynamics when dorzagliatin and sitagliptin given alone and in combination will be studied.
Interventions
- DRUG Sitagliptin
- DRUG Dorzagliatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2019-01-31 |
| Est. Completion | 2019-08-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03790839
The ClinicalTrials.gov registry entry for NCT03790839 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hua Medicine Limited, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sitagliptin is the first listed.
NCT03790839 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03790839 about?
NCT03790839 is a clinical study titled "Drug Interaction Study Between Dorzagliatin and Sitagliptin". This is a Phase 1, open-label, sequential, multiple-dose, drug interaction study of glucokinase activator dorzagliatin and sitagliptin in subjects with T2DM. Pharmacokinetics and pharmacodynamics when dorzagliatin and sitagliptin given alone and in combination will be studied.
What is the current status of trial NCT03790839?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2019-01-31. Estimated completion is 2019-08-30.
What interventions are being tested in trial NCT03790839?
The interventions under investigation include: Sitagliptin (DRUG), Dorzagliatin (DRUG).
Who is sponsoring clinical trial NCT03790839?
This trial is sponsored by Hua Medicine Limited, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.